Following “lower than expected demand,” Nestlé is exploring strategic options for Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first and only drug approved by the US FDA for the treatment of peanut allergy in children. Possible causes for the slow uptake of Palforzia include the COVID-19 pandemic, frequent doctor’s visits with additional time when escalating doses, and complicated billing procedures. Nevertheless, Palforzia is covered by many insurance plans.
The Food Allergy Bravery Clinic at Children’s Hospital of Philadelphia provides cognitive behavioral therapy to children who have severe food allergy-related anxiety, helping them reduce their fears and improve their quality of life. The Food Allergy Bravery Clinic at CHOP is the first of its kind and available to children and adolescents of all ages. During treatment, patients take small steps towards facing allergen-related fears and building confidence around food and social situations. In a study evaluating the program’s effectiveness, patients showed significant reductions on two standardized scales of anxiety.